EP3769757A3 - Bildgebung von histondeacetylasen mit einem radiotracer mittels positronenemissionstomografie - Google Patents

Bildgebung von histondeacetylasen mit einem radiotracer mittels positronenemissionstomografie Download PDF

Info

Publication number
EP3769757A3
EP3769757A3 EP20190478.6A EP20190478A EP3769757A3 EP 3769757 A3 EP3769757 A3 EP 3769757A3 EP 20190478 A EP20190478 A EP 20190478A EP 3769757 A3 EP3769757 A3 EP 3769757A3
Authority
EP
European Patent Office
Prior art keywords
radiotracer
positron emission
emission tomography
histone deacetylases
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20190478.6A
Other languages
English (en)
French (fr)
Other versions
EP3769757A2 (de
Inventor
Jacob M. Hooker
Changning Wang
Frederick Albert SCHROEDER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP3769757A2 publication Critical patent/EP3769757A2/de
Publication of EP3769757A3 publication Critical patent/EP3769757A3/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nuclear Medicine (AREA)
  • Furan Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20190478.6A 2013-10-18 2014-10-17 Bildgebung von histondeacetylasen mit einem radiotracer mittels positronenemissionstomografie Pending EP3769757A3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892966P 2013-10-18 2013-10-18
PCT/US2014/061179 WO2015058106A1 (en) 2013-10-18 2014-10-17 Imaging histone deacetylases with a radiotracer using positron emission tomography
EP14853451.4A EP3062783B1 (de) 2013-10-18 2014-10-17 Bildgebung von histondeacetylasen mit einem radiotracer mittels positronenemissionstomografie

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP14853451.4A Division EP3062783B1 (de) 2013-10-18 2014-10-17 Bildgebung von histondeacetylasen mit einem radiotracer mittels positronenemissionstomografie

Publications (2)

Publication Number Publication Date
EP3769757A2 EP3769757A2 (de) 2021-01-27
EP3769757A3 true EP3769757A3 (de) 2021-10-06

Family

ID=52828752

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20190478.6A Pending EP3769757A3 (de) 2013-10-18 2014-10-17 Bildgebung von histondeacetylasen mit einem radiotracer mittels positronenemissionstomografie
EP14853451.4A Active EP3062783B1 (de) 2013-10-18 2014-10-17 Bildgebung von histondeacetylasen mit einem radiotracer mittels positronenemissionstomografie

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14853451.4A Active EP3062783B1 (de) 2013-10-18 2014-10-17 Bildgebung von histondeacetylasen mit einem radiotracer mittels positronenemissionstomografie

Country Status (4)

Country Link
US (3) US10188756B2 (de)
EP (2) EP3769757A3 (de)
AU (1) AU2014337102B2 (de)
WO (1) WO2015058106A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810508B (zh) * 2017-01-05 2019-12-10 浙江农林大学暨阳学院 一种铁催化多组分反应合成苯并[1,4]-氧氮杂卓化合物的方法
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN110770206B (zh) * 2017-04-11 2022-11-25 通用医疗公司 Hdac6抑制剂
TWI650139B (zh) * 2017-10-11 2019-02-11 行政院原子能委員會核能硏究所 含有放射性同位素氟的異羥肟酸類造影劑、其製備方法及其用途
US11481934B2 (en) * 2018-10-10 2022-10-25 New York University System, method, and computer-accessible medium for generating magnetic resonance imaging-based anatomically guided positron emission tomography reconstruction images with a convolutional neural network

Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026696A1 (en) * 2000-09-29 2002-04-04 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
WO2002026703A1 (en) * 2000-09-29 2002-04-04 Prolifix Limited Carbamic acid compounds comprising an ether linkage as hdac inhibitors
WO2002046144A1 (en) * 2000-12-07 2002-06-13 F. Hoffmann-La Roche Ag Tetralone derivatives as antitumor agents
WO2002062773A1 (en) * 2001-01-27 2002-08-15 F. Hoffmann-La Roche Ag Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors
WO2003024448A2 (en) * 2001-09-14 2003-03-27 Methylgene, Inc. Inhibitors of histone deacetylase
WO2003070691A1 (fr) * 2002-02-21 2003-08-28 Osaka Industrial Promotion Organization Derive de n-hydroxycarboxamide
WO2003076422A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
WO2003087066A1 (en) * 2002-04-11 2003-10-23 Sk Chemicals, Co., Ltd. α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
WO2004013130A1 (en) * 2002-08-02 2004-02-12 Argenta Discovery Limited Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
EP1401824A2 (de) * 2001-06-15 2004-03-31 F. Hoffman-la Roche AG Aromatische hydroxamsäurederivate, die sich als hdac inhibitoren eignen
WO2004035525A1 (en) * 2002-10-17 2004-04-29 Methylgene Inc. Inhibitors of histone deacetylase
CN1513839A (zh) * 2003-07-04 2004-07-21 深圳微芯生物科技有限责任公司 具有分化和抗增殖活性的苯甲酰胺类组蛋白去乙酰化酶抑制剂及其药用制剂
WO2004069823A1 (en) * 2003-02-04 2004-08-19 Methylgene, Inc. Inhibitors of histone deacetylase
WO2004069803A2 (en) * 2003-02-06 2004-08-19 F. Hoffmann-La Roche Ag Mono-acylated o-phenylendiamines derivatives and their use against cancer
WO2004072047A1 (en) * 2003-02-11 2004-08-26 Fujisawa Pharmaceutical Co., Ltd. Indoles, benzimidazoles or naphhimidazoles as histone deacetylase (hdac) inhibitors
WO2004092115A2 (en) * 2003-04-07 2004-10-28 Axys Pharmaceuticals Inc. Hydroxamates as therapeutic agents
EP1485378A1 (de) * 2002-03-13 2004-12-15 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- und morpholinylderivate als neue inhibitoren von histon-deacetylase
WO2005030705A1 (en) * 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
WO2005040101A1 (en) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Acylurea connected and sulfonylurea connected hydroxamates
WO2005075469A1 (en) * 2004-02-04 2005-08-18 Argenta Discovery Limited Thiazolyl-hydroxamic acids and thiadiazolyl-hydroxamic acids, and use thereof for treating diseases associated with histone deacetylase enzymatic activity
WO2005086898A2 (en) * 2004-03-08 2005-09-22 Miikana Therapeutics, Inc. Inhibitors of histone deacetylase
WO2005087724A2 (en) * 2004-03-11 2005-09-22 Altana Pharma Ag Sulphonylpyrroles as hdac inhibitors
WO2005092899A1 (en) * 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
WO2005121073A1 (en) * 2004-06-10 2005-12-22 Cancer Research Technology Limited Inhibitors of histone deacetylase
WO2006010750A1 (en) * 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
WO2006101455A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications
US7154002B1 (en) * 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007017728A2 (en) * 2005-08-05 2007-02-15 Orchid Research Laboratories Limited Novel heterocyclic compounds
WO2007054776A2 (en) * 2005-11-10 2007-05-18 Orchid Research Laboratories Limited Stilbene like compounds as novel hdac inhibitors
WO2008036046A1 (en) * 2006-09-20 2008-03-27 S*Bio Pte Ltd IMIDAZO[l,2-a]PYRIDINE HYDROXYMATE COMPOUNDS THAT ARE INHIBITORS OF HISTONE DEACETYLASE
WO2008075757A1 (en) * 2006-12-15 2008-06-26 Astellas Pharma Inc. N-hydroxyacrylamide compounds
WO2010043953A2 (en) * 2008-10-15 2010-04-22 Orchid Research Laboratories Ltd. Novel bridged cyclic compounds as histone deacetylase inhibitors
WO2011019393A2 (en) * 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
WO2011058582A1 (en) * 2009-11-16 2011-05-19 Orchid Research Laboratories Ltd. Histone deacetylase inhibitors for the treatment of fungal infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT103200B (pt) 2004-09-30 2006-08-24 Taguspark-Soc. Prom.Desenv.Parq.Ci.Tec.Area Lisboa Sistema de tomografia por emissão de positrões (pet)
WO2009047615A2 (en) 2007-10-10 2009-04-16 Orchid Research Laboratories Limited Novel histone deacetylase inhibitors
CN101970399A (zh) * 2007-12-14 2011-02-09 乔治敦大学 组蛋白脱乙酰酶抑制剂
US20120077774A1 (en) 2009-05-28 2012-03-29 Cornell University Compositions and their use for removing cholesterol
US20110312956A1 (en) 2010-06-16 2011-12-22 Paul Jackson ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING
US9540395B2 (en) * 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors

Patent Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026703A1 (en) * 2000-09-29 2002-04-04 Prolifix Limited Carbamic acid compounds comprising an ether linkage as hdac inhibitors
WO2002026696A1 (en) * 2000-09-29 2002-04-04 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
WO2002046144A1 (en) * 2000-12-07 2002-06-13 F. Hoffmann-La Roche Ag Tetralone derivatives as antitumor agents
WO2002062773A1 (en) * 2001-01-27 2002-08-15 F. Hoffmann-La Roche Ag Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors
EP1401824A2 (de) * 2001-06-15 2004-03-31 F. Hoffman-la Roche AG Aromatische hydroxamsäurederivate, die sich als hdac inhibitoren eignen
WO2003024448A2 (en) * 2001-09-14 2003-03-27 Methylgene, Inc. Inhibitors of histone deacetylase
WO2003070691A1 (fr) * 2002-02-21 2003-08-28 Osaka Industrial Promotion Organization Derive de n-hydroxycarboxamide
WO2003076422A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
EP1485378A1 (de) * 2002-03-13 2004-12-15 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- und morpholinylderivate als neue inhibitoren von histon-deacetylase
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
WO2003087066A1 (en) * 2002-04-11 2003-10-23 Sk Chemicals, Co., Ltd. α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
WO2004013130A1 (en) * 2002-08-02 2004-02-12 Argenta Discovery Limited Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
US7154002B1 (en) * 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2004035525A1 (en) * 2002-10-17 2004-04-29 Methylgene Inc. Inhibitors of histone deacetylase
WO2004069823A1 (en) * 2003-02-04 2004-08-19 Methylgene, Inc. Inhibitors of histone deacetylase
WO2004069803A2 (en) * 2003-02-06 2004-08-19 F. Hoffmann-La Roche Ag Mono-acylated o-phenylendiamines derivatives and their use against cancer
WO2004072047A1 (en) * 2003-02-11 2004-08-26 Fujisawa Pharmaceutical Co., Ltd. Indoles, benzimidazoles or naphhimidazoles as histone deacetylase (hdac) inhibitors
WO2004092115A2 (en) * 2003-04-07 2004-10-28 Axys Pharmaceuticals Inc. Hydroxamates as therapeutic agents
CN1513839A (zh) * 2003-07-04 2004-07-21 深圳微芯生物科技有限责任公司 具有分化和抗增殖活性的苯甲酰胺类组蛋白去乙酰化酶抑制剂及其药用制剂
WO2005030705A1 (en) * 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
WO2005040101A1 (en) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Acylurea connected and sulfonylurea connected hydroxamates
WO2005075469A1 (en) * 2004-02-04 2005-08-18 Argenta Discovery Limited Thiazolyl-hydroxamic acids and thiadiazolyl-hydroxamic acids, and use thereof for treating diseases associated with histone deacetylase enzymatic activity
WO2005086898A2 (en) * 2004-03-08 2005-09-22 Miikana Therapeutics, Inc. Inhibitors of histone deacetylase
WO2005087724A2 (en) * 2004-03-11 2005-09-22 Altana Pharma Ag Sulphonylpyrroles as hdac inhibitors
WO2005092899A1 (en) * 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
WO2005121073A1 (en) * 2004-06-10 2005-12-22 Cancer Research Technology Limited Inhibitors of histone deacetylase
WO2006010750A1 (en) * 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
WO2006101455A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications
WO2007017728A2 (en) * 2005-08-05 2007-02-15 Orchid Research Laboratories Limited Novel heterocyclic compounds
WO2007054776A2 (en) * 2005-11-10 2007-05-18 Orchid Research Laboratories Limited Stilbene like compounds as novel hdac inhibitors
WO2008036046A1 (en) * 2006-09-20 2008-03-27 S*Bio Pte Ltd IMIDAZO[l,2-a]PYRIDINE HYDROXYMATE COMPOUNDS THAT ARE INHIBITORS OF HISTONE DEACETYLASE
WO2008075757A1 (en) * 2006-12-15 2008-06-26 Astellas Pharma Inc. N-hydroxyacrylamide compounds
WO2010043953A2 (en) * 2008-10-15 2010-04-22 Orchid Research Laboratories Ltd. Novel bridged cyclic compounds as histone deacetylase inhibitors
WO2011019393A2 (en) * 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
WO2011058582A1 (en) * 2009-11-16 2011-05-19 Orchid Research Laboratories Ltd. Histone deacetylase inhibitors for the treatment of fungal infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOPALAN BALASUBRAMANIAN ET AL: "Discovery of adamantane based highly potent HDAC inhibitors", BIORGANIC & MEDICINAL CHEMISTRY LETTERS,, vol. 23, no. 9, 14 March 2013 (2013-03-14), pages 2532 - 2537, XP028546972, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2013.03.002 *
M KALISZCZAK ET AL: "A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth", BRITISH JOURNAL OF CANCER, vol. 108, no. 2, 5 February 2013 (2013-02-05), GB, pages 342 - 350, XP055385986, ISSN: 0007-0920, DOI: 10.1038/bjc.2012.576 *

Also Published As

Publication number Publication date
EP3769757A2 (de) 2021-01-27
US20190240357A1 (en) 2019-08-08
US20160271276A1 (en) 2016-09-22
US10188756B2 (en) 2019-01-29
US10842891B2 (en) 2020-11-24
AU2014337102B2 (en) 2019-02-28
WO2015058106A1 (en) 2015-04-23
EP3062783B1 (de) 2020-08-12
US20210030899A1 (en) 2021-02-04
EP3062783A1 (de) 2016-09-07
AU2014337102A1 (en) 2016-06-02
EP3062783A4 (de) 2017-08-02

Similar Documents

Publication Publication Date Title
CY1120188T1 (el) ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6
CY1118572T1 (el) Παραγωγο κυκλοαλκανιου
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
TR201911151T4 (tr) Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
MX2017014809A (es) Amidas heterociclicas como inhibidores de cinasa.
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
MX356341B (es) Agente de control de endoparasitos.
EA201690127A1 (ru) Состав на основе ингибиторов syk
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX351581B (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
WO2014188178A9 (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
RS54730B1 (sr) Inhibitori beta sekretaze
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
UA117251C2 (uk) 4-членні кільцеві карбоксамідні сполуки, що застосовуються як нематоциди
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX351225B (es) Derivado de sulfonamida y uso medicinal del mismo.
EP3769757A3 (de) Bildgebung von histondeacetylasen mit einem radiotracer mittels positronenemissionstomografie
PH12015501813A1 (en) Monocyclic pyridine derivative
IN2014DN07509A (de)
CY1118371T1 (el) Αναστολεις του iap
MX2015017156A (es) Inhibidores de bace.
MX2017005158A (es) Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk).
EA201591349A1 (ru) Способ получения вортиоксетина
CY1124643T1 (el) Νεα ενωση και φαρμακευτικα αποδεκτο αλας αυτης

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3062783

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HOOKER, JACOB, M.

Inventor name: WANG, CHANGNING

Inventor name: SCHROEDER, FREDERICK, ALBERT

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 259/06 20060101ALI20210830BHEP

Ipc: A61K 31/16 20060101AFI20210830BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220406

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230518

17Q First examination report despatched

Effective date: 20230612